Lazard Asset Management LLC Myovant Sciences Ltd. Transaction History

Lazard Asset Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	BUY	$7.78 - $14.69 $43,902 - $82,895	5,643 New	5,643 $70,000
Q1 2022 May 13, 2022	SELL	$11.38 - $16.4 $43,278 - $62,369	-3,803 Closed	0 $0
Q4 2021 Feb 09, 2022	BUY	$14.31 - $23.87 $46,221 - $77,100	3,230 Added 563.7%	3,803 $59,000
Q3 2021 Nov 15, 2021	SELL	$18.94 - $26.99 $35,758 - $50,957	-1,888 Reduced 76.72%	573 $12,000
Q2 2021 Aug 12, 2021	BUY	$17.07 - $24.56 $42,009 - $60,442	2,461 New	2,461 $56,000
Q4 2020 Feb 11, 2021	SELL	$13.8 - $27.62 $4,857 - $9,722	-352 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$14.05 - $22.6 $4,945 - $7,955	352 New	352 $4,000
Q1 2019 May 13, 2019	SELL	$16.83 - $24.45 $428,205 - $622,081	-25,443 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$19.33 - $26.78 $211,740 - $293,348	10,954 Added 75.6%	25,443 $675,000
Q2 2018 Aug 13, 2018	BUY	$19.2 - $25.14 $278,188 - $364,253	14,489 New	14,489 $331,000

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Lazard Asset Management LLC with notifications on news.